Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
  • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
  • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/28—Phosphorus compounds with one or more P—C bonds
  • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
  • C07F9/40—Esters thereof
  • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
  • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl

Definitions

• P2X purinoreceptors are a family of ion channels that are activated by extracellular adenosine triphosphate (ATP). Purinoreceptors have been implicated in a variety of biological functions.
• the P2X3 receptor subunit is a member of this family. It was originally cloned from rat dorsal root ganglia. Chen et al., Nature , vol. 377, pp. 428-431 (1995). The nucleotide and amino acid sequences of both rat and human P2X3 are now known. Lewis, et al., Nature , vol. 377, pp. 432-435 (1995); and Garcia-Guzman, et al., Brain Res. Mol. Brain Res., vol. 47, pp. 59 66 (1997).
• P2X3 antagonists are processes for the synthesis of P2X3 antagonists, wherein the P2X3 antagonist is methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[l,2- a]pyri din-3 -yl)methyl)morpholine-4-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof.
• Compound 1 (Compound 1), comprising contacting a compound with the structure: amide coupling reagent and methylamine, or a salt thereof.
• the amide coupling reagent is carbonyldiimidazole.
• the amide coupling reagent is propanephosphonic acid anhydride (T3P).
• the hydrogenation catalyst is palladium on carbon, palladium hydroxide, rhodium on carbon, rhodium on alumina, platinum oxide, or platinum on carbon. In some embodiments, the hydrogenation catalyst is palladium on carbon.
• amide coupling reagent is carbonyldiimidazole.
• the amide coupling reagent is propanephosphonic acid anhydride (T3P).
• the compound with the structure is aqueous tetrahydrofuran, dioxane, 2-methyl tetrahydrofuran, aqueous methanol, aqueous ethanol, or aqueous acetonitrile.
• the solvent is aqueous tetrahydrofuran.
• the base is lithium hydroxide.
• agent is copper(II) bromide.
• the brominating agent is liquid bromine.
• the compound with the structure pared by a process comprising contacting a compound with the structure: hydrogenation catalyst and hydrogen.
• the hydrogenation catalyst is palladium on carbon, palladium hydroxide, rhodium on carbon, rhodium on alumina, platinum oxide, or platinum on carbon. In some embodiments, the hydrogenation catalyst is palladium on carbon.
• subject or “patient” encompasses mammals and non-mammals.
• mammals include, but are not limited to, any member of the Mammalian class: humans, non human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
• non mammals include, but are not limited to, birds, fish and the like.
• the mammal is a human.
• treatment or “treating “ or “palliating” or “ameliorating” are used interchangeably herein. These terms refers to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit.
• therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
• a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient is still afflicted with the underlying disorder.
• the compositions are administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has been made.
• “Pharmaceutically acceptable salt” includes both acid and base addition salts.
• a pharmaceutically acceptable salt of any one of the compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms.
• Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
• “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and. aromatic sulfonic acids, etc.
• acetic acid trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
• Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like.
• salts of amino acids such as arginates, gluconates, and galacturonates (see, for example, Berge S.M. etal, “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 66:1-19 (1997)).
• Acid addition salts of basic compounds are prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt.
• “Pharmaceutically acceptable base addition salt” refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
• Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, A-dibenzyl ethyl enedi amine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N- methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine,
• pharmaceutical combination means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
• fixed combination means that the active ingredients, are both administered to a patient simultaneously in the form of a single entity or dosage.
• non-fixed combination means that the active ingredients, are administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific intervening time limits, wherein such administration provides effective levels of the two compounds in the body of the patient.
• cocktail therapy e.g. the administration of three or more active ingredients.
• co-administration or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.
• activator is used in this specification to denote any molecular species that results in activation of the indicated receptor, regardless of whether the species itself binds to the receptor or a metabolite of the species binds to the receptor when the species is administered topically.
• the activator can be a ligand of the receptor or it can be an activator that is metabolized to the ligand of the receptor, i.e., a metabolite that is formed in tissue and is the actual ligand.
• antagonist refers to a small -molecule agent that binds to a nuclear hormone receptor and subsequently decreases the agonist induced transcriptional activity of the nuclear hormone receptor.
• agonist refers to a small-molecule agent that binds to a nuclear hormone receptor and subsequently increases nuclear hormone receptor transcriptional activity in the absence of a known agonist.
• inverse agonist refers to a small-molecule agent that binds to a nuclear hormone receptor and subsequently decreases the basal level of nuclear hormone receptor transcriptional activity that is present in the absence of a known agonist.
• modulate means to interact with a target protein either directly or indirectly so as to alter the activity of the target protein, including, by way of example only, to inhibit the activity of the target, or to limit or reduce the activity of the target.
• a modulator refers to a compound that alters an activity of a target.
• a modulator can cause an increase or decrease in the magnitude of a certain activity of a target compared to the magnitude of the activity in the absence of the modulator.
• a modulator is an inhibitor, which decreases the magnitude of one or more activities of a target.
• an inhibitor completely prevents one or more activities of a target.
• the P2X3 antagonist described herein is methyl (S)-2-((2-(2,6- difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[l,2-a]pyridin-3-yl)methyl)morpholine- 4-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof.
• Compound 1 has the structure:
• the starting material for the synthesis of Compound some embodiments an intermediate in the synthesis of Compound some embodiments, an intermediate in the synthesis of Compound some embodiments, an intermediate in the synthesis of Compound in the synthesis of Compound
• an intermediate in the synthesis of Compound 1 is , d
• the P2X3 antagonist described herein is methyl (S)-2-((2-(2,6- difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[l,2-a]pyridin-3-yl)methyl)morpholine- 4-carboxylate (Compound 1), or a pharmaceutically acceptable salt thereof.
• Compound 1 has the structure:
• the starting material for the synthesis of Compound 1 is
• an intermediate in the synthesis of Compound 1 is to 8 carbon atoms. In some embodiments, an intermediate in the synthesis of Compound 1 is some embodiments, an intermediate in the synthesis of Compound 1 is O CC ⁇ Me
• an intermediate in the synthesis of Compound 1 is
• an intermediate in the synthesis of Compound 1 is me embodiments, an intermediate in the synthesis of Compound 1 is some embodiments, an intermediate in the synthesis of Compound 1 is branched alkyl group comprising 1 to 8 carbon atoms.
• an intermediate in the synthesis of Compound 1 is ,
• an intermediate in the synthesis of Compound 1 is hydrogen, or a straight chain or branched alkyl group comprising 1 to 8 carbon atoms.
• an intermediate in the synthesis of Compound some embodiments an intermediate in the synthesis of Compound where X is Br.
• an intermediate in the synthesis of Compound 1 is some embodiments, an intermediate in the synthesis of Compound some embodiments, an intermediate in the synthesis of Compound hydrogen, or a straight chain or branched alkyl group comprising 1 to 8 carbon atoms.
• an intermediate in the synthesis of Compound some embodiments an intermediate in the synthesis of Compound .
• an intermediate in the synthesis of Compound 1 is straight chain or branched alkyl group comprising 1 to 8 carbon atoms.
• an intermediate in the synthesis of Compound 1 is some embodiments, an intermediate in the synthesis of Compound some embodiments, an intermediate in the synthesis of Compound where X is Br.
• an intermediate in the synthesis of Compound 1 is some embodiments, an intermediate in the synthesis of Compound some embodiments, an intermediate in the synthesis of Compound hydrogen, or a straight chain or branched alkyl group comprising 1 to 8 carbon
• the compounds described herein may in some cases exist as diastereomers, enantiomers, or other stereoisomeric forms.
• the compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. Separation of stereoisomers may be performed by chromatography or by the forming diastereomeric and separation by recrystallization, or chromatography, or any combination thereof. (Jean Jacques, Andre Collet, Samuel H. Wilen, “Enantiomers, Racemates and Resolutions”, John Wiley And Sons, Inc., 1981, herein incorporated by reference for this disclosure). Stereoisomers may also be obtained by stereoselective synthesis.
• compounds may exist as tautomers. All tautomers are included within the formulas described herein.
• the compounds described herein exist as their pharmaceutically acceptable salts.
• the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts.
• the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
• the compounds described herein possess acidic or basic groups and therefore react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
• these salts are prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
• the pharmaceutically acceptable salt of Compound 1 is an acetate, benzoate, besylate, bitartrate, carbonate, citrate, fumarate, gluconate, hydrobromide, hydrochloride, maleate, mesylate, nitrate, phosphate, salicylate, succinate, sulfate, or tartrate salt.
• the pharmaceutically acceptable salt of Compound l is a mono hydrochloride salt.
• the pharmaceutically acceptable salt of Compound 1 is a mono-hydrochloride salt.
• the compounds described herein exist as solvates.
• the invention provides for methods of treating diseases by administering such solvates.
• the invention further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.
• Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and, in some embodiments, are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein are conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein are conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran or methanol.
• the compounds provided herein exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
• the compounds described herein exist in their isotopically-labeled forms.
• the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds.
• the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds as pharmaceutical compositions.
• the compounds disclosed herein include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
• isotopes that are incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chloride, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 C1, respectively.
• Compounds described herein, and pharmaceutically acceptable salts, esters, solvate, hydrates or derivatives thereof which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
• Certain isotopically-labeled compounds for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays.
• Tritiated, i. e., 3 H and carbon-14, i. e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavy isotopes such as deuterium, z.e., 2 H, produces certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Increased levels of deuterium incorporation produce a detectable kinetic isotope effect (KIE) that may affect the pharmacokinetic, pharmacologic and/or toxicologic parameters of Compound 1 in comparison to Compound 1 having naturally occurring levels of deuterium.
• KIE detectable kinetic isotope effect
• the isotopically labeled compound, or a pharmaceutically acceptable salt thereof is prepared by any suitable method. [0068] In some embodiments, at least one hydrogen in Compound 1 is replaced with deuterium.
• the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
• the synthesis of compounds described herein are accomplished using means described in the chemical literature, using the methods described herein, or by a combination thereof.
• solvents, temperatures and other reaction conditions presented herein may vary.
• the starting materials and reagents used for the synthesis of the compounds described herein are synthesized or are obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, FischerScientific (Fischer Chemicals), and AcrosOrganics.
• the compounds described herein, and other related compounds having different substituents are synthesized using techniques and materials described herein as well as those that are recognized in the field, such as described, for example, in Fieser and Fieser’s Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd’s Chemistry of Carbon Compounds, Volumes 1-5 and Supplemental (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock’s Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4 th Ed., (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4 th Ed., Vols.
• the amide coupling reagent is carbonyldiimidazole.
• the amide coupling reagent is propanephosphonic acid anhydride (T3P).
• the amide coupling reagent is a carbodiimide coupling agent.
• the amide coupling reagent is l-ethyl-3-(3-dimethylaminopropyl)carbodiimide. In some embodiments, the amide coupling reagent is 1 -ethyl-3 -(3 -dimethylaminopropyl)carbodiimide with added N- hy droxyb enzotri azol e .
• the compound with the structure prepared by a process comprising contacting a compound with the structure: -amino-4-methylpyridine.
• the process comprises contacting a compound with the structure: -amino-4-methylpyridine and sodium borohydride.
• the process comprises contacting a compound with the structure: -amino-4-methylpyridine in the presence of a solvent.
• the solvent is acetonitrile.
• nt is N-bromosuccinimide.
• the brominating agent is copper(II) bromide. In some embodiments, the brominating agent is liquid bromine.
• he hydrogenation catalyst is palladium on carbon, palladium hydroxide, rhodium on carbon, rhodium on alumina, platinum oxide, or platinum on carbon. In some embodiments, the hydrogenation catalyst is palladium on carbon.
• the compound with the structure solvent.
• the process comprises contacting a compound with the structure: base and sodium borohydride in the presence of a solvent.
• the process comprises contacting a compound with the structure: base and no sodium borohydride in the presence of a solvent.
• the solvent is aqueous tetrahydrofuran, dioxane, 2-methyl tetrahydrofuran, aqueous methanol, aqueous ethanol, or aqueous acetonitrile. In some embodiments, the solvent is aqueous tetrahydrofuran.
• the base is lithium hydroxide. In some embodiments, the base is sodium hydroxide. In some embodiments, the base is potassium hydroxide.
• the base is lithium diisopropylamide.
• the compound with the structure pared by a process comprising contacting a compound with the hydrogenation catalyst and hydrogen.
• the hydrogenation catalyst is palladium on carbon, palladium hydroxide, rhodium on carbon, rhodium on alumina, platinum oxide, or platinum on carbon. In some embodiments, the hydrogenation catalyst is palladium on carbon.
• Furth - disclosed herein is a process for the preparation of methyl (S)-2-((2-(2,6- difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[l,2-a]pyridin-3-yl)methyl)morpholine- 4-carboxylate (Compound 1), comprising: the reaction of a compound with the structure: c°r 'OH
• compositions and methods of administration are provided.
• P2X3 antagonist as described herein can be in any pharmacological form including a therapeutically effective amount of an P2X3 antagonist alone or in combination with a pharmaceutically acceptable carrier.
• compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Additional details about suitable excipients for pharmaceutical compositions described herein may be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A.
• a pharmaceutical composition refers to a mixture of Compound 1 described herein, with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
• the pharmaceutical composition facilitates administration of the compound to an organism.
• therapeutically effective amounts of compounds described herein are administered in a pharmaceutical composition to a mammal having a disease, disorder, or condition to be treated.
• the mammal is a human.
• a therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors.
• Compound lean be used singly or in combination with one or more therapeutic agents as components of mixtures (as in combination therapy).
• compositions described herein can be administered to a subject by multiple administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes.
• parenteral e.g., intravenous, subcutaneous, intramuscular
• intranasal e.g., buccal
• topical e.g., topical, rectal, or transdermal administration routes.
• compositions described herein which include Compound 1 described herein, can be formulated into any suitable dosage form, including but not limited to, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations.
• aqueous oral dispersions liquids, gels, syrups, elixirs, slurries, suspensions, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release
• Compound 1 is formulated in a tablet dosage form. In some embodiments, Compound 1 is formulated in a capsule dosage form. In some embodiments, Compound 1 is formulated in a suspension dosage form. In some embodiments, Compound 1 is formulated as powder-in-capsule dosage form. In some embodiments, Compound 1 is formulated as a powder-in-bottle for reconstitution as a suspension.
• compositions including a compound described herein may be manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
• Dose administration can be repeated depending upon the pharmacokinetic parameters of the dosage formulation and the route of administration used.
• Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
• the specification for the dosage unit forms are dictated by and directly dependent on (a) the unique characteristics of Compound 1 and the particular therapeutic effect to be achieved and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
• the specific dose can be readily calculated by one of ordinary skill in the art, e.g., according to the approximate body weight or body surface area of the patient or the volume of body space to be occupied.
• the dose will also be calculated dependent upon the particular route of administration selected. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those of ordinary skill in the art. Exact dosages are determined in conjunction with standard dose-response studies. It will be understood that the amount of the composition actually administered will be determined by a practitioner, in the light of the relevant circumstances including the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration.
• the compounds described herein can be used in the preparation of medicaments for the modulation of P2X3, or for the treatment of diseases or conditions that would benefit, at least in part, from modulation of P2X3.
• a method for treating any of the diseases or conditions described herein in a subject in need of such treatment involves administration of pharmaceutical compositions containing at least one compound described herein, or a pharmaceutically acceptable salt, or pharmaceutically acceptable solvate or hydrate thereof, in therapeutically effective amounts to said subject.
• compositions containing the compound(s) described herein can be administered for prophylactic and/or therapeutic treatments.
• the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest the symptoms of the disease or condition. Amounts effective for this use will depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician.
• compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition. Such an amount is defined to be a "prophylactically effective amount or dose.”
• a patient susceptible to or otherwise at risk of a particular disease, disorder or condition is defined to be a "prophylactically effective amount or dose.”
• dose a pharmaceutically effective amount or dose.
• the precise amounts also depend on the patient's state of health, weight, and the like.
• effective amounts for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician.
• the administration of the compounds may be administered chronically, that is, for an extended period of time, including throughout the duration of the patient’s life in order to ameliorate or otherwise control or limit the symptoms of the patient’s disease or condition.
• the administration of the compounds may be given continuously; alternatively, the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday”).
• the length of the drug holiday can vary between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days.
• the dose reduction during a drug holiday may be from about 10% to about 100%, including, by way of example only, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%.
• a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, can be reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. Patients can, however, require intermittent treatment on a long term basis upon any recurrence of symptoms.
• the amount of a given agent that will correspond to such an amount will vary depending upon factors such as the particular compound, disease or condition and its severity, the identity (e.g., weight) of the subject or host in need of treatment, but can nevertheless be determined in a manner recognized in the field according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated.
• doses employed for adult human treatment will typically be in the range of about 0.01 mg per day to about 5000 mg per day, in some embodiments, about 1 mg per day to about 1500 mg per day.
• the desired dose may conveniently be presented in a single dose or as divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.
• the pharmaceutical composition described herein may be in unit dosage forms suitable for single administration of precise dosages.
• the formulation is divided into unit doses containing appropriate quantities of one or more compound.
• the unit dosage may be in the form of a package containing discrete quantities of the formulation.
• Non-limiting examples are packaged tablets or capsules, and powders in vials, capsules, bottles, or ampoules.
• Aqueous suspension compositions can be packaged in single-dose non-reclosable containers.
• multiple-dose reclosable containers can be used, in which case it is typical to include a preservative in the composition.
• formulations for parenteral injection may be presented in unit dosage form, which include, but are not limited to ampoules, or in multi-dose containers, with an added preservative.
• Step 1 The hydroxymethyl group of A (106 kg, 487.9 mole) was oxidized to the corresponding aldehyde B at a temperature of -3°C to 1.5°C under biphasic conditions (dichloromethane-water) by reaction with sodium bromide, sodium bicarbonate, catalytic TEMPO (2,2,6,6,-tetramethyl-l-piperidinyloxy, free radical) and sodium hypochlorite (added dropwise over ⁇ 10 h while maintaining a temperature of -3°C to 1.5°C). After stirring an additional 2 h, the reaction was quenched at -5°C to 0°C using sodium thiosulfate and stirred for 30 minutes.
• Step 2 The biphasic system from above containing aldehyde B was treated in portions at 5°C to 10°C with commercially available (carbethoxymethylene)triphenylphosphorane. After stirring for 1 h at 8°C to 15°C, water was added, the mixture was stirred for 30 minutes, the layers were separated, and the aqueous layer was extracted with additional dichloromethane.
• commercially available (carbethoxymethylene)triphenylphosphorane After stirring for 1 h at 8°C to 15°C, water was added, the mixture was stirred for 30 minutes, the layers were separated, and the aqueous layer was extracted with additional dichloromethane.
• Step 3 The solution of C in THF was treated dropwise with a solution of 3M NaOH over 2 hours at 15°C to 25°C. The mixture was then warmed to 25°C to 35°C and stirred for 8 hours. The mixture was cooled to 20°C to 25°C, MTBE was added, and the layers were separated. The organic layer was extracted with water and, while maintaining the temperature at below 15°C, the combined aqueous layers containing the sodium salt of D were acidified slowly with 3N HC1 until the pH was 10-11. The aqueous mixture was then washed with dichloromethane to remove any residual triphenylphosphine oxide and then slowly acidified to pH 5 using 3N HC1 while maintaining a temperature below 15°C. The resulting mixture was extracted with dichloromethane and the organic extracts containing D were concentrated. THF was then added and evaporated. The crude product D was dissolved in THF and used directly in the following step.
• Step 4 The solution of D in THF (43.7 kg by assay) was charged to a hydrogenation reactor. A THF slurry of Pd/C (2.90 kg) was added, and the resulting mixture was stirred under hydrogen (-145 psi) at 25°C to 49°C for 12 h. The mixture was filtered under nitrogen, the filter cake was washed with THF and the filtrate was concentrated. Dichloromethane was added and concentrated to remove THF and the operation was repeated. Fresh dichloromethane was added to the mixture and the resulting solution of E (43.5 kg based on assay) was used directly in the following step.
• Step 5 A solution of E in dichloromethane at 10°C to 15°C was treated with N- hydroxybenzotriazole (HOBT), N, O-dimethylhydroxylamine hydrochloride, and triethylamine. l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) was then added in portions. The mixture was stirred at 15°C to 25°C for 12 h. Water was added, the resulting mixture was stirred for 12 h, and the layers were separated. The aqueous layer was separated and extracted with fresh dichloromethane. The combined organic layers were washed with sodium bicarbonate solution to remove HOBT and dried.
• HOBT N- hydroxybenzotriazole
• EDCI l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
• Step 6 A solution of 3,5-difluorobenzoic acid, tert-butyl ester in THF was cooled to -65°C under nitrogen and treated dropwise with 1.5 equivalents of LDA solution. The mixture was stirred at -60° to -65°C for 1 h and then treated dropwise with a solution of compound F (37 kg) in THF. The reaction was stirred between -65°C and -60°C for 6 h and then quenched at -65°C with a solution of acetic acid in THF. The temperature was raised to -33°C and the mixture was stirred for 30 minutes. Ethyl acetate was added and the mixture was diluted with brine. The layers were separated and the organic layer was washed with brine and then concentrated to generate a solution of compound G in ethyl acetate which was used directly in the next step.
• Step 7 HC1 gas (60.4 kg) was bubbled into ethyl acetate (360 kg) between -6°C and 0°C. Compound G was added to the mixture over 2 h at a temperature of 20°C to 25°C. The reaction was then stirred for 16 h, filtered, and the product was washed with ethyl acetate and MTBE and dried under vacuum to afford H.
• Step 8 Methanol was charged into a reactor at 26°C, and cooled to -7°C. HC1 was then bubbled into the methanol at -7°C to 0°C over 8 h. Compound H (28.8 kg) was added at 2°C and the mixture was heated to 40°C to 50°C and then stirred for 6 h. The reaction was then concentrated and the residual dichloromethane solvent was swapped initially to heptane (addition of heptane followed by concentration) and then to THF (addition of THF followed by concentration). The resulting solution of compound I was used directly in the next step.
• Step 9 A solution of compound I (-24.6 kg) in THF was diluted with water, the mixture was cooled to -5°Cto 0°C, and the pH was adjusted to 7-8 using sodium bicarbonate solution (2.5 equiv bicarbonate). An additional 2 equivalents of sodium bicarbonate were added and methyl chloroformate (1.2 equivalents) was added dropwise over 1.5 h and the reaction was stirred at -5°C to 0°C for 1.5 h. Water, ethyl acetate, and 2N HC1 were added, the layers were separated, and the organic layer was washed with brine and then concentrated. Additional ethyl acetate was added and evaporated to generate an ethyl acetate solution of J.
• the combined organic layers were washed with water at 0°C to 10°C, 7% sodium bicarbonate solution at 0° to 10°, and then water.
• the organic layer was treated with silica gel and the mixture was concentrated to dryness below 35°C.
• the residue was transferred to a silica pad which was eluted with di chi orom ethane-ethyl acetate (1 V/9V) and the fractions containing compound L were concentrated and diluted with THF. This was repeated until the residual ethyl acetate was ⁇ 1%.
• the aqueous layer was extracted with fresh dichloromethane and the combined organic layers were washed twice with 27% ammonium chloride solution and then twice with water.
• the organic layer containing compound 1 was cycled through activated carbon for 1 to 3 h using a CUNO filter.
• the filtrate was concentrated to 1-2 V below 35°C and the dichloromethane was exchanged with ethyl acetate through successive addition/evaporation operations until the residual dichloromethane was ⁇ 1%.
• Ethyl acetate (2-4 V) was added.
• a mixture of compound 1 in ethyl acetate was stirred at 45°C to 55°C for 1 to 2 h, cooled to 20°C to 30°C and then stirred for 1 to 2 h.
• Compound 1 was filtered and washed with ethyl acetate, and dried.
• Compound 1 was treated with water/methanol (1V/7V; 6.5-7.9 kg) and stirred at 47°C to 55°C under nitrogen for 0.5 to 3 h until a clear solution was obtained. The solution was polish filtered and the original reactor was rinsed with methanol/water. The mixture was warmed to 47°C to 55°C and stirred for 10 minutes to 30 minutes to obtain a clear solution. Water (8 kg) was added under nitrogen while maintaining the temperature and the mixture was seeded. The mixture was stirred at 47°C to 55°C under nitrogen for 3 h to 6 h and then cooled to 22°C to 27°C over 5 h. The mixture was stirred for 12 h to 24 h and filtered under nitrogen. Compound 1 was washed with water/methanol (2/1.8) and dried at 47°C to 53°C.
• Example 3 Alternative synthesis of methyl (S)-2-((2-(2,6-difluoro-4- (methylcarbamoyl)phenyl)-7-methylimidazo[l,2-a]pyridin-3-yl)methyl)morpholine-4- carboxylate (Compound 1) [00127] A solution of starting material A (30 g, 0.138 mole) in ethyl acetate (100 mL) was treated with DMSO (129 g, 1.66 mole, 117 mL; 12 equiv) while maintaining the temperature at ⁇ 30°C.
• the reaction was cooled to -5°C to 5°C and a 20% aqueous solution of oxone (1 equivalent) was added while maintaining the temperature. The mixture was then stirred for 1 h while maintaining the temperature at -5°C to 5°C. The pH was then adjusted to 3-5 using 85% H3PO4. The reaction was filtered and the filter cake was washed with fresh ethyl acetate (10 V). The layers were separated and the layers were separated and the aqueous phase was extracted with ethyl acetate (2 X 20 volumes). The organic layers were combined and washed with water (2 X 10 volumes). The organic solution was concentrated to afford compound N which was recrystallized from 2 volumes of acetonitrile by cooling at -15°C to 5°C to afford N (64% overall yield for the 2 steps from compound A).
• the sodium salt was converted to the carboxylic acid by addition to water and adjusting the pH to 3 using 3M HC1.
• the resulting mixture was extracted with ethyl acetate and the organic extracts were concentrated.
• the product Q was recrystallized from ethyl acetate: methyl cyclohexane (1.5 V: 10 V).
• a solution of R in DCM was concentrated to a small volume and the DCM was exchanged for acetonitrile (total of 10 V of acetonitrile).
• 2-amino-4-methylpyridine (5 equivalents relative to R) was added and the reaction was stirred at 50°C for 24 h and then at 80°C for 16 h.
• the reaction mixture was concentrated to remove acetonitrile and a mixture of dichloromethane (8 volumes)-water (3 volumes) was added.
• the mixture was cooled to 0-10°C and the pH was adjusted to 2.5 using 2N HC1.
• the aqueous layer was extracted with dichloromethane and the organic layer was concentrated and the solvent was exchanged for THF.
• the pH was then adjusted to 2.0-4.0 using -275 g of 18% sulfuric acid (temperature maintained at ⁇ 10°C). An additional 250 mL of water was added and the organic layer was separated. The organic layer was washed using 7% sodium bicarbonate and then concentrated to 2-3 volumes while maintaining the temperature at ⁇ 40°C. Toluene (170 mL) was added and the resulting solution was concentrated to 2-3 volumes while maintaining the temperature at ⁇ 40°C. Acetic acid (944 mL) was added and the resulting solution containing U was used directly in the next step.
• Trifluoroacetic acid (220.8 g, 1.937 mole) was added dropwise at ⁇ 40°C to the solution of U prepared in the previous step. The resulting mixture was stirred at 85°C to 95°C for 12-24 h. The mixture was then concentrated to 2-3 volumes at a temperature of ⁇ 70°. While maintaining a temperature of 20°C to 30°C, water (1.44 L) was added dropwise and the resulting mixture was stirred for 2-4 h. The product was filtered and washed with water (-140 mL). The product was treated with methyl tert-butyl ether (133 mL) and the resulting slurry was stirred at -20°C to -5°C for 1-2 h. The product was filtered and washed with a methyl tert-butyl ether and then dried at 50°C to 60°C to afford intermediate V (115 g).
• Example 4 Potency and Selectivity for Human P2X3 and P2X2/3 Receptors
• the ability of compound 1 described herein to act as an antagonist of the P2X3 and P2X2/P2X3 channel (encoded by the human P2RX2 and P2RX3 genes, stably expressed in HEK293 cells) was evaluated with a Fluo-8 calcium kit.
• Compound 1 was evaluated at twelve concentrations.
• the cells were pre-incubated with Compound 1 for 20 minutes, then stimulated with the P2X3 and P2X2/P2X3 agonist a,b-methyleneATP (meATP) at final concentrations of 3 mM and 30 mM.
• P2X3 and P2X2/P2X3 agonist a,b-methyleneATP (meATP) at final concentrations of 3 mM and 30 mM.
• meATP a,b-methyleneATP
• ionomycin was added at a final concentration of 5 mM in order to obtain the maximum calcium influx and fluorescence signal possible from the cells. Fluorescence was recorded continuously for 10 minutes, starting 10 seconds prior to the addition of meATP.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (4)

Publications (1)

Family

ID=77292130

Family Applications (1)

Country Status (11)

Cited By (9)

Citations (2)

Family Cites Families (8)

• 2021
  • 2021-02-12 CN CN202180028877.XA patent/CN115427419B/zh active Active
  • 2021-02-12 JP JP2022548876A patent/JP7693691B2/ja active Active
  • 2021-02-12 EP EP21754068.1A patent/EP4103572A4/en active Pending
  • 2021-02-12 WO PCT/IB2021/000130 patent/WO2021161109A1/en not_active Ceased
  • 2021-02-12 US US17/929,027 patent/US12503470B2/en active Active
  • 2021-02-12 AU AU2021219992A patent/AU2021219992A1/en not_active Abandoned
  • 2021-02-12 IL IL295394A patent/IL295394A/en unknown
  • 2021-02-12 BR BR112022015818A patent/BR112022015818A2/pt unknown
  • 2021-02-12 CA CA3184277A patent/CA3184277A1/en active Pending
  • 2021-02-12 MX MX2022009765A patent/MX2022009765A/es unknown
  • 2021-02-12 KR KR1020227031508A patent/KR20220140804A/ko active Pending

Patent Citations (2)

Non-Patent Citations (12)

Also Published As

Similar Documents

Legal Events